CAMBRIDGE, Mass. — The Precision Medicine World Conference 2026 (PMWC 2026), held March 4–6 in Silicon Valley, convened researchers, clinicians, and technology leaders to discuss advances in precision medicine and the integration of artificial intelligence into biomedical research. The 2026 meeting coincided with the 25th anniversary of the first draft publication of the Human Genome Project first draft publication, highlighting the continued convergence of genomics, computational biology, and AI.
At the conference, Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, chaired the Precision Aging and Longevity track and presented the PMWC Luminary Award to Greg Brockman, President and Co-Founder of OpenAI, recognizing contributions to the development of artificial intelligence technologies with broad scientific impact.
The event marked a milestone for Insilico Medicine. In 2015, the company received the PMWC Emerging Company Award for early work applying generative artificial intelligence and machine learning to drug discovery. At the time, PMWC Co-Founder and President Tal Behar noted the potential for AI technologies to transform aging and longevity research.
Ten years later, Zhavoronkov returned to the PMWC stage as a track chair and presenter, reflecting the growing role of AI-enabled approaches in biomedical research and drug development.
As chair of the AI-Driven Biomarkers to Quantify Aging session, Zhavoronkov moderated a discussion on computational approaches to measuring biological age and identifying biomarkers of aging.
Panel participants included:
Steve Horvath, Principal Investigator at the Altos Labs Cambridge Institute of Science and a pioneer in the development of epigenetic aging clocks
Mahdi Moqri, MD, PhD, of Harvard University and Co-Director of the Biomarkers of Aging Consortium
The discussion addressed how machine learning approaches are being applied to genomic, epigenetic, and clinical datasets to better quantify biological aging and potentially inform interventions targeting age-related diseases.
PMWC 2026 also recognized leading figures in technology and innovation. Steve Wozniak, Co-Founder of Apple, received the conference’s Pioneer Award, while Brockman received the Luminary Award for contributions to the development of advanced AI systems.
The recognition reflects a broader trend discussed throughout the conference: artificial intelligence is increasingly being integrated into multiple stages of biomedical research, from biomarker discovery to therapeutic development.
Insilico Medicine continues to develop generative AI models for biology and chemistry aimed at accelerating drug discovery and advancing precision medicine approaches to aging and age-related diseases.
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround - from project initiation to preclinical candidate (PCC) nomination - of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com .
Forward-Looking Statements:
This press release contains forward-looking statements relating to the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial performance. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends”, “visions”, “schedule” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company at the time of this press release in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations.
All of the forward-looking statements made in this press release are qualified by these statements. Consequently, the inclusion of forward-looking statements in this press release should not be regarded as representations by the Board or the Company that the plans and objectives will be achieved, and investors should not place undue reliance on such statements.
The Company, its Board, the employees and the agents of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this press release; and (b) no liability for any losses in the event that any of the forward-looking statements do not materialise or turn out to be incorrect.